Covid-19 roundup: Merck prepares new study on their $425M Covid drug; COVAX begins rollout but huge disparities still loom
Merck spent $425 million to buy out OncoImmune in November, presumably under the belief that they could scale up their drug for severe Covid …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
